Alivus Life Sciences reports FY26 Profit for Year Rs. 5,644.83 Million
RESULTS
▲ Positive Development
LOW RISK
📅 Filed on BSE: 14 May 2026, 07:34 PM IST · BSE ID: d0550e87-7189-4b1c-a32b-016e94261d78
View Original BSE Filing (PDF)
💡
In Simple Terms
The company announced its yearly financial results, reporting a profit of Rs. 5,644.83 Million and proposing a dividend.
🤖 AI Summary
- Alivus Life Sciences reported Profit for the Year of Rs. 5,644.83 Million for FY26
- Revenue from Operations for the year ended March 31, 2026, was Rs. 25,518.32 Million
- Board of Directors recommended a final dividend of Rs. 5/- (250%) per equity share of Rs. 2 each
- Total Income for the year ended March 31, 2026, stood at Rs. 26,122.43 Million
- Cash generated from operating activities for FY26 was Rs. 5,654.13 Million
🔢 Key Numbers — exact figures from BSE filing, not rounded
Revenue from Operations (Year ended 31 Mar'26)
Rs. 25,518.32 Million
7.92%
Profit for the Year (Year ended 31 Mar'26)
Rs. 5,644.83 Million
16.24%
Basic Earnings per equity share (Year ended 31 Mar'26)
Rs. 45.99
16.05%
Total Equity (As at 31 Mar'26)
Rs. 33,321.32 Million
18.27%
Net Cash Generated from Operating Activities (Year ended 31 Mar'26)
Rs. 5,654.13 Million
44.42%
Recommended Final Equity Dividend
Rs. 5/- per equity share
🏢 How This Affects the Company
The company's Revenue from Operations increased, indicating continued sales growth in its core business activities.
Profit for the Year increased to Rs. 5,644.83 Million, supporting an increase in Other Equity to Rs. 33,075.85 Million and strong cash generation from operations.
Capital Work-in-Progress increased significantly to Rs. 2,734.04 Million, suggesting ongoing investments in expanding or upgrading operational assets.
👥 What This Means For Shareholders
✅
Action Required
Shareholders must approve the recommended final equity dividend at the ensuing Annual General Meeting.
👤
Who Is Affected
All shareholders holding equity shares of Alivus Life Sciences Ltd. will be eligible for the recommended dividend of Rs. 5/- per equity share upon approval.
🔍
Management Signal
The recommendation of a final dividend reflects the Board's intent to distribute a portion of the company's earnings to shareholders.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Annual General Meeting date – monitor for dividend approval and record date
Quarterly financial results for June 30, 2026 – observe revenue and profit trends
Updates on Capital Work-in-Progress – track investment progress and impact
LOW RISK
The financial results indicate positive performance and operational cash generation.
💡 Investor Takeaway
Alivus Life Sciences reported a Profit for the Year of Rs. 5,644.83 Million for FY26, a 16.24% increase from Rs. 4,856.27 Million in FY25. The Board recommended a final dividend of Rs. 5/- (250%) per equity share of Rs. 2 each, signaling confidence.
⚖️ Strengths & Concerns
✅ Positives
- Profit for the Year increased to Rs. 5,644.83 Million for FY26, up from Rs. 4,856.27 Million in FY25.
- Net Cash Generated from Operating Activities was robust at Rs. 5,654.13 Million for FY26, compared to Rs. 3,915.24 Million in FY25.
⚠️ Concerns
- Cash and Cash Equivalents decreased to Rs. 19.82 Million as of March 31, 2026, from Rs. 710.62 Million as of March 31, 2025.
- Investments in Mutual Funds increased to Rs. 7,803.79 Million from Rs. 4,776.15 Million, but were partly offset by redemption of Mutual Funds of Rs. 2,302.92 Million.
📅 Company Track Record
No previous filings were found for Alivus Life Sciences Ltd. within the provided context. The company was formerly Glenmark Life Sciences Limited, incorporated on July 14, 2011 (CIN: L74900PN2011PLC139963). This filing provides its first publicly available financial results on ForgeUp.
Based on publicly available historical data. For context only.